Deintensification to a fixed mixture of insulin glargine and lixisenatide as a way to modern antidiabetic therapy in patients with type 2 diabetes mellitus
Abstract
At present, the so-called fixed-ratio combination therapy (FRC) is available, which allows to apply a GLP-1 receptor agonist (GLP-1 RA) and a basal insulin analogue together using one injector once a day. Many patients treated with multiple dose insulin therapy (MDI) do not meet the targets in spite of following complex insulin regimen with a number of limitations in everyday life.
This article presents the real-life evidence in people who were treated with MDI in history and transferred to the FRC regimen, thus underwent deintensification. Fixed mixture of glargine 100 U/ml and GLP-1 RA lixisenatide, IGlarLixi, was used.
It is a retrospective analysis of data from medical records. Within 3 months there was a slight decrease in HbA1c by 2.25 mmol/mol (95% CI: -3.83 to -0.67), p < 0.05, the total daily dose of insulin decreased by 7.8 IU/day (95% CI: -13.7 to -1.9), p < 0.05, and patient comfort was significantly increased by reducing the number of applications per day and the incidence of hypoglycaemia decreased.
Deintensification has a potential to improve quality of life and comfort in many people with type 2 diabetes mellitus overtreated by complex insulin regimens.